Effect of the strength of adsorption of hepatitis B surface antigen to aluminum hydroxide adjuvant on the immune response

Bethany Hansen, Mary Belfast, George Soung, Liping Song, Patricia M. Egan, Robert Capen, Harm HogenEsch, Ralph Mancinelli, Stanley L. Hem

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Hepatitis B surface antigen (HBsAg) is known to adsorb to aluminum hydroxide adjuvant (AH) by ligand exchange between its accessible phosphate groups and surface hydroxyl groups of the adjuvant. To study the effect of the binding strength, five vaccines were prepared with AH or four samples of AH that were modified by pretreatment with different concentrations of potassium dihydrogen phosphate. The adsorptive coefficients ranged from 3660 to 250 mL/mg based on the Langmuir adsorption isotherm and degrees of elution ranged from 1 to 31% when the vaccines were exposed to interstitial fluid in vitro. When tested in mice the four vaccines containing phosphate-treated AH (PTAH) induced significantly greater antibody responses than the vaccine containing AH, which had the highest adsorptive coefficient and the smallest degree of elution of HBsAg. The results indicated that antibody production is reduced when the antigen is adsorbed too strongly. Thus, the strength of adsorption of the antigen to an aluminum-containing adjuvant can affect the immunogenicity of the vaccine and should be optimized during vaccine formulation.

Original languageEnglish (US)
Pages (from-to)888-892
Number of pages5
JournalVaccine
Volume27
Issue number6
DOIs
StatePublished - Feb 5 2009
Externally publishedYes

Fingerprint

Aluminum Hydroxide
aluminum hydroxide
Hepatitis B Surface Antigens
Adsorption
adjuvants
adsorption
Vaccines
immune response
vaccines
Antibody Formation
Phosphates
Antigens
Extracellular Fluid
potassium dihydrogen phosphate
phosphates
Aluminum
antigens
Hydroxyl Radical
extracellular fluids
antibody formation

Keywords

  • Adsorptive coefficient
  • Aluminum hydroxide adjuvant
  • Antigen adsorption
  • Degree of elution
  • Hepatitis B surface antigen
  • Immunogenicity
  • Ligand exchange

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Effect of the strength of adsorption of hepatitis B surface antigen to aluminum hydroxide adjuvant on the immune response. / Hansen, Bethany; Belfast, Mary; Soung, George; Song, Liping; Egan, Patricia M.; Capen, Robert; HogenEsch, Harm; Mancinelli, Ralph; Hem, Stanley L.

In: Vaccine, Vol. 27, No. 6, 05.02.2009, p. 888-892.

Research output: Contribution to journalArticle

Hansen, B, Belfast, M, Soung, G, Song, L, Egan, PM, Capen, R, HogenEsch, H, Mancinelli, R & Hem, SL 2009, 'Effect of the strength of adsorption of hepatitis B surface antigen to aluminum hydroxide adjuvant on the immune response', Vaccine, vol. 27, no. 6, pp. 888-892. https://doi.org/10.1016/j.vaccine.2008.11.078
Hansen, Bethany ; Belfast, Mary ; Soung, George ; Song, Liping ; Egan, Patricia M. ; Capen, Robert ; HogenEsch, Harm ; Mancinelli, Ralph ; Hem, Stanley L. / Effect of the strength of adsorption of hepatitis B surface antigen to aluminum hydroxide adjuvant on the immune response. In: Vaccine. 2009 ; Vol. 27, No. 6. pp. 888-892.
@article{0e5b68d03f6e4b91af7d4692fc5bef77,
title = "Effect of the strength of adsorption of hepatitis B surface antigen to aluminum hydroxide adjuvant on the immune response",
abstract = "Hepatitis B surface antigen (HBsAg) is known to adsorb to aluminum hydroxide adjuvant (AH) by ligand exchange between its accessible phosphate groups and surface hydroxyl groups of the adjuvant. To study the effect of the binding strength, five vaccines were prepared with AH or four samples of AH that were modified by pretreatment with different concentrations of potassium dihydrogen phosphate. The adsorptive coefficients ranged from 3660 to 250 mL/mg based on the Langmuir adsorption isotherm and degrees of elution ranged from 1 to 31{\%} when the vaccines were exposed to interstitial fluid in vitro. When tested in mice the four vaccines containing phosphate-treated AH (PTAH) induced significantly greater antibody responses than the vaccine containing AH, which had the highest adsorptive coefficient and the smallest degree of elution of HBsAg. The results indicated that antibody production is reduced when the antigen is adsorbed too strongly. Thus, the strength of adsorption of the antigen to an aluminum-containing adjuvant can affect the immunogenicity of the vaccine and should be optimized during vaccine formulation.",
keywords = "Adsorptive coefficient, Aluminum hydroxide adjuvant, Antigen adsorption, Degree of elution, Hepatitis B surface antigen, Immunogenicity, Ligand exchange",
author = "Bethany Hansen and Mary Belfast and George Soung and Liping Song and Egan, {Patricia M.} and Robert Capen and Harm HogenEsch and Ralph Mancinelli and Hem, {Stanley L.}",
year = "2009",
month = "2",
day = "5",
doi = "10.1016/j.vaccine.2008.11.078",
language = "English (US)",
volume = "27",
pages = "888--892",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "6",

}

TY - JOUR

T1 - Effect of the strength of adsorption of hepatitis B surface antigen to aluminum hydroxide adjuvant on the immune response

AU - Hansen, Bethany

AU - Belfast, Mary

AU - Soung, George

AU - Song, Liping

AU - Egan, Patricia M.

AU - Capen, Robert

AU - HogenEsch, Harm

AU - Mancinelli, Ralph

AU - Hem, Stanley L.

PY - 2009/2/5

Y1 - 2009/2/5

N2 - Hepatitis B surface antigen (HBsAg) is known to adsorb to aluminum hydroxide adjuvant (AH) by ligand exchange between its accessible phosphate groups and surface hydroxyl groups of the adjuvant. To study the effect of the binding strength, five vaccines were prepared with AH or four samples of AH that were modified by pretreatment with different concentrations of potassium dihydrogen phosphate. The adsorptive coefficients ranged from 3660 to 250 mL/mg based on the Langmuir adsorption isotherm and degrees of elution ranged from 1 to 31% when the vaccines were exposed to interstitial fluid in vitro. When tested in mice the four vaccines containing phosphate-treated AH (PTAH) induced significantly greater antibody responses than the vaccine containing AH, which had the highest adsorptive coefficient and the smallest degree of elution of HBsAg. The results indicated that antibody production is reduced when the antigen is adsorbed too strongly. Thus, the strength of adsorption of the antigen to an aluminum-containing adjuvant can affect the immunogenicity of the vaccine and should be optimized during vaccine formulation.

AB - Hepatitis B surface antigen (HBsAg) is known to adsorb to aluminum hydroxide adjuvant (AH) by ligand exchange between its accessible phosphate groups and surface hydroxyl groups of the adjuvant. To study the effect of the binding strength, five vaccines were prepared with AH or four samples of AH that were modified by pretreatment with different concentrations of potassium dihydrogen phosphate. The adsorptive coefficients ranged from 3660 to 250 mL/mg based on the Langmuir adsorption isotherm and degrees of elution ranged from 1 to 31% when the vaccines were exposed to interstitial fluid in vitro. When tested in mice the four vaccines containing phosphate-treated AH (PTAH) induced significantly greater antibody responses than the vaccine containing AH, which had the highest adsorptive coefficient and the smallest degree of elution of HBsAg. The results indicated that antibody production is reduced when the antigen is adsorbed too strongly. Thus, the strength of adsorption of the antigen to an aluminum-containing adjuvant can affect the immunogenicity of the vaccine and should be optimized during vaccine formulation.

KW - Adsorptive coefficient

KW - Aluminum hydroxide adjuvant

KW - Antigen adsorption

KW - Degree of elution

KW - Hepatitis B surface antigen

KW - Immunogenicity

KW - Ligand exchange

UR - http://www.scopus.com/inward/record.url?scp=58249106119&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58249106119&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2008.11.078

DO - 10.1016/j.vaccine.2008.11.078

M3 - Article

C2 - 19071182

AN - SCOPUS:58249106119

VL - 27

SP - 888

EP - 892

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 6

ER -